What to Expect in Neuromodulation This Year

The spinal cord stimulation (SCS) market growth should improve in 2020 as leaders in the space launch new products and benefit from recent acquisitions and invest in potential indication expansions, according to Needham & Co.'s Mike Matson. The medtech analyst published a report Monday sharing his takeaways from the North American Neuromodulation Society (NANS) meeting in Las Vegas, NV over the weekend. Matson noted that SCS device market growth should continue to improve in 2020 and beyond, thanks to a number of factors. The analyst estimates that SCS currently represents about $2.5 billion, which accounts for roughly 70% of the larger neuromodulation market (the remaining 30% being deep brain stimulation). SCS market growth slowed in 2018 and 2019 but Matson expects that the market should return to growth this year. Drivers of this anticipated growth, according to Matson's report, include Medtronic's recent acquisition of Bloomington, IL-based Stimgenics; Boston Scientific's combination therapy, and Nevro's recent launch of the Senza Omnia SCS system. Nevro received FDA approval for the Senza Omnia SCS System (shown below on the right) in November. The Omnia system includes a new programmer designed to make it easy for physicians to offer a wider array of waveforms across the full SCS frequency spectrum, either separately or paired together. The new system also includes a redesigned patient remote t...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news